MARKET OUTLOOK
SLE is an autoimmune disease that can manifest in many different organs, including the kidneys. Renal inflammation associated with SLE, also known as lupus nephritis, is among the most serious manifestations of the disease. Presently, no therapies are specifically approved for lupus nephritis. Current treatment involves drugs such as antimalarials (e.g., hydroxychloroquine), immunosuppressants (e.g., mycophenolate mofetil), biologics (e.g., Genentech/Biogen’s Rituxan), and corticosteroids. In this content, we offer valuable insights into the disease’s treatment algorithm, physician prescribing behavior, and current therapies’ patient share. A better understanding of lupus nephritis management will help pharmaceutical companies make informed decisions in this space.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
GEOGRAPHIES
United States
PRIMARY RESEARCH
Survey of 50 rheumatologists and 50 nephrologists in the United States.
KEY DRUGS COVERED
Mycophenolate mofetil/sodium, cyclophosphamide, azathioprine, tacrolimus, hydroxychloroquine, cyclosporine, Rituxan (rituximab), Benlysta (belimumab)
KEY INSIGHTS PROVIDED